当前位置： SCI文献检索 > CANCER TREATMENT REVIEWS期刊下所有文献 > Second-line treatment options in metastatic castration-resistant prostate cancer: a comparison of key trials with recently approved agents.

Second-line treatment options in metastatic castration-resistant prostate cancer: a comparison of key trials with recently approved agents.

Abstract：

:Standard first-line treatment for metastatic castration-resistant prostate cancer (mCRPC) is docetaxel plus prednisone; however, patients will usually experience disease progression during or after docetaxel treatment due to inherent or acquired resistance. Before 2010, second-line options for mCRPC were limited. However, cabazitaxel, abiraterone acetate and enzalutamide have since been approved for patients with mCRPC whose disease has progressed during or after receiving docetaxel, based on the Phase III trials TROPIC, COU-AA-301 and AFFIRM. In all three trials, an overall survival benefit (primary endpoint) was seen in the experimental arm compared with the control arm: 15.1 vs. 12.7months for cabazitaxel plus prednisone compared with mitoxantrone plus prednisone in TROPIC (hazard ratio [HR] 0.70; P<0.0001); 14.8 vs. 10.9months for abiraterone acetateplus prednisone compared with placebo plus prednisone in COU-AA-301 (HR 0.65; P<0.001); and 18.4 vs. 13.6months for enzalutamide compared with placebo alone in AFFIRM (0.63; P<0.001). However, differences in patient populations, comparators, and selection and/or definition of secondary endpoints make it difficult to draw direct cross-trial comparisons. Radium-223 dichloride has also been approved for patients with mCRPC with metastases to bone but not other organs. To date, no comparative trials or sequencing studies with newer agents have been performed. Without such data, treatment decisions must be based on evaluation of the existing evidence. This commentary compares and contrasts study designs and key data from each of these Phase III trials, and also discusses recent and ongoing clinical trials with new agents in the first- and second-line settings in mCRPC.

journal_name

Cancer Treat Rev

journal_title

Cancer treatment reviews

authors

Bahl A,Masson S,Birtle A,Chowdhury S,de Bono J

doi

10.1016/j.ctrv.2013.06.008

subject

Has Abstract

pub_date

2014-02-01 00:00:00

pages

170-7

issue

1

eissn

0305-7372

issn

1532-1967

pii

S0305-7372(13)00131-X

journal_volume

40

pub_type

杂志文章,评审

相关文献

CANCER TREATMENT REVIEWS文献大全
  • Improving attribution of adverse events in oncology clinical trials.

    abstract：:Attribution of adverse events (AEs) is critical to oncology drug development and the regulatory process. However, processes for determining the causality of AEs are often sub-optimal, unreliable, and inefficient. Thus, we conducted a toxicity-attribution workshop in Silver Springs MD to develop guidance for improving ...

    journal_title：Cancer treatment reviews

    pub_type： 杂志文章,评审

    doi：10.1016/j.ctrv.2019.04.004

    authors： George GC,Barata PC,Campbell A,Chen A,Cortes JE,Hyman DM,Jones L,Karagiannis T,Klaar S,Le-Rademacher JG,LoRusso P,Mandrekar SJ,Merino DM,Minasian LM,Mitchell SA,Montez S,O'Connor DJ,Pettit S,Silk E,Sloan JA,Stewar

    更新日期：2019-06-01 00:00:00

  • Comparison of outcomes and toxicities among radiation therapy treatment options for prostate cancer.

    abstract：:We review radiation therapy (RT) options available for prostate cancer, including external beam (EBRT; with conventional fractionation, hypofractionation, stereotactic body RT [SBRT]) and brachytherapy (BT), with an emphasis on the outcomes, toxicities, and contraindications for therapies. PICOS/PRISMA methods were us...

    journal_title：Cancer treatment reviews

    pub_type： 杂志文章,评审

    doi：10.1016/j.ctrv.2016.06.006

    authors： Zaorsky NG,Shaikh T,Murphy CT,Hallman MA,Hayes SB,Sobczak ML,Horwitz EM

    更新日期：2016-07-01 00:00:00

  • Molecular targeted therapy of glioblastoma.

    abstract：:Glioblastomas are intrinsic brain tumors thought to originate from neuroglial stem or progenitor cells. More than 90% of glioblastomas are isocitrate dehydrogenase (IDH)-wildtype tumors. Incidence increases with age, males are more often affected. Beyond rare instances of genetic predisposition and irradiation exposur...

    journal_title：Cancer treatment reviews

    pub_type： 杂志文章,评审

    doi：10.1016/j.ctrv.2019.101896

    authors： Le Rhun E,Preusser M,Roth P,Reardon DA,van den Bent M,Wen P,Reifenberger G,Weller M

    更新日期：2019-11-01 00:00:00

  • Management of a novel immune deficiency with IL-2 therapy.

    abstract：:The present study describes a female child, who had a primary defect in the ability of her T-cells to secrete interleukin-2. Numbers of B- and T-cells were normal, but their functions were severely deficient. The patient had decreased immunoglobulins and poor ability to mount antibody responses. Phytohemagglutinin (PH...

    journal_title：Cancer treatment reviews

    pub_type： 杂志文章

    doi：10.1016/0305-7372(89)90034-0

    authors： Pahwa R,Paradise C,Good RA

    更新日期：1989-06-01 00:00:00

  • PARP inhibitors in ovarian cancer.

    abstract：:Poly-ADP-ribosepolymerase inhibitors (PARPis) are the most active and interesting therapies approved for the treatment of epithelial ovarian cancer. They have changed the clinical management of a disease characterized, in almost half of cases, by extreme genetic complexity and alteration of DNA damage repair pathways,...

    journal_title：Cancer treatment reviews

    pub_type： 杂志文章,评审

    doi：10.1016/j.ctrv.2018.12.002

    authors： Franzese E,Centonze S,Diana A,Carlino F,Guerrera LP,Di Napoli M,De Vita F,Pignata S,Ciardiello F,Orditura M

    更新日期：2019-02-01 00:00:00

  • Maintenance chemotherapy for non-small-cell lung cancer.

    abstract：:Currently, platinum-based combination chemotherapy is the standard first-line chemotherapy for non-small-cell lung cancer (NSCLC). Historically, platinum-based chemotherapy has been recommended for up to six cycles even for responders, and second-line chemotherapy has been considered when disease progression is confir...

    journal_title：Cancer treatment reviews

    pub_type： 杂志文章,评审

    doi：10.1016/j.ctrv.2010.12.007

    authors： Kim YH,Mishima M

    更新日期：2011-11-01 00:00:00

  • New approaches to the systemic treatment of melanoma.

    abstract：:Metastatic melanoma is an incurable condition with a median survival of about 6 months. Chemotherapy can result in objective tumour responses but only in a minority of cases and remissions are short-lived, 3-6 months. DTJC is the most active single agent with response rates of 15-20% and although combination chemother...

    journal_title：Cancer treatment reviews

    pub_type： 杂志文章,评审

    doi：10.1053/ctrv.1999.0138

    authors： Chowdhury S,Vaughan MM,Gore ME

    更新日期：1999-10-01 00:00:00

  • Updated use of TACE for hepatocellular carcinoma treatment: How and when to use it based on clinical evidence.

    abstract：:Hepatocellular carcinoma (HCC) is the most common primary liver cancer, representing the sixth leading cause of cancer and the third leading cause of cancer-related mortality. Patient stratification and treatment allocation are based on tumor stage, liver function, and performance status. According to the Barcelona Cl...

    journal_title：Cancer treatment reviews

    pub_type： 杂志文章,评审

    doi：10.1016/j.ctrv.2018.11.002

    authors： Raoul JL,Forner A,Bolondi L,Cheung TT,Kloeckner R,de Baere T

    更新日期：2019-01-01 00:00:00

  • Locoregional radiological treatment for hepatocellular carcinoma; Which, when and how?

    abstract：:Hepatocellular carcinoma (HCC) is one of the most frequent and deadliest cancers worldwide. Liver transplantation, surgical resection or local ablation offer the best survival advantages but most patients either present when the tumor is in an advanced stage or the degree of underlying liver disease precludes these op...

    journal_title：Cancer treatment reviews

    pub_type： 杂志文章,评审

    doi：10.1016/j.ctrv.2011.05.002

    authors： Meza-Junco J,Montano-Loza AJ,Liu DM,Sawyer MB,Bain VG,Ma M,Owen R

    更新日期：2012-02-01 00:00:00

  • Biliary tract cancers: molecular profiling as a tool for treatment decisions. A literature review.

    abstract：:Biliary tract cancer is a quite rare disease; despite recent significant advances in imaging modalities, most of the patients have advanced disease at presentation thus making radical surgery not feasible. Many different chemotherapeutic regimens have been investigated in small uncontrolled studies, with generally dis...

    journal_title：Cancer treatment reviews

    pub_type： 杂志文章,评审

    doi：10.1016/j.ctrv.2006.03.003

    authors： Berardi R,Scartozzi M,Freddari F,Squadroni M,Santinelli A,Bearzi I,Fabris G,Cascinu S

    更新日期：2006-08-01 00:00:00

  • How did lomustine become standard of care in recurrent glioblastoma?

    abstract：:Glioblastomas are the most common malignant primary intrinsic brain tumors. Their incidence increases with age, and males are more often affected. First-line management includes maximum safe surgical resection followed by involved-field radiotherapy plus concomitant and six cycles of maintenance temozolomide chemother...

    journal_title：Cancer treatment reviews

    pub_type： 杂志文章,评审

    doi：10.1016/j.ctrv.2020.102029

    authors： Weller M,Le Rhun E

    更新日期：2020-07-01 00:00:00

  • Participation of adolescents with cancer in clinical trials.

    abstract：:Adolescent patients with cancer reside in a "no-man's land" between the world of pediatric oncology and that of "adult" medical oncology. As compared to younger and older patients, adolescents and young adults are under-represented on clinical trials. This relative lack of participation in clinical protocols has been ...

    journal_title：Cancer treatment reviews

    pub_type： 杂志文章,评审

    doi：10.1016/j.ctrv.2006.11.005

    authors： Ferrari A,Bleyer A

    更新日期：2007-11-01 00:00:00

  • Efficacy of ifosfamide in refractory malignant diseases and uroprotection by mesna: results of a clinical phase II-study with 151 patients.

    abstract：:In a clinical phase II study 151 patients with refractory malignant diseases were treated with ifosfamide (60 mg/kg/day i.v. days 1-5, q 21-28 days). Altogether, 490 courses of treatment were given, 92 with conventional prophylactic measures (continuous infusion of 3-4 litre physiological saline plus alkalinization of...

    journal_title：Cancer treatment reviews

    pub_type： 杂志文章

    doi：10.1016/s0305-7372(83)80013-9

    authors： Scheulen ME,Niederle N,Bremer K,Schütte J,Seeber S

    更新日期：1983-09-01 00:00:00

  • The emerging role of MET/HGF inhibitors in oncology.

    abstract：:The N-methyl-N'-nitroso-guanidine human osteosarcoma transforming gene (MET) receptor tyrosine kinase and its ligand hepatocyte growth factor (HGF) control cellular signaling cascades that direct cell growth, proliferation, survival, and motility. Aberrant MET/HGF activation has been observed in many tumor types, can ...

    journal_title：Cancer treatment reviews

    pub_type： 杂志文章,meta分析,评审

    doi：10.1016/j.ctrv.2013.02.001

    authors： Scagliotti GV,Novello S,von Pawel J

    更新日期：2013-11-01 00:00:00

  • Advances in neoadjuvant therapy for colorectal cancer with liver metastases.

    abstract：:Metastatic colorectal cancer (CRC) is most frequently seen in the liver. Resection of metastases remains the treatment of choice; however, the majority of patients are ineligible for surgery due to unfavorable location, size, or number of metastases; insufficient liver reserve; or extrahepatic disease. The activity of...

    journal_title：Cancer treatment reviews

    pub_type： 杂志文章,评审

    doi：10.1016/j.ctrv.2008.01.004

    authors： Pozzo C,Barone C,Kemeny NE

    更新日期：2008-06-01 00:00:00

  • Safety of cranial radiotherapy concurrent with tyrosine kinase inhibitors in non-small cell lung cancer patients: A systematic review.

    abstract：:Recently, non-small cell lung cancer (NSCLC) has been partly subclassified into molecularly-defined oncogene "addicted" tumors for which targeted agents are available. Tyrosine kinase inhibitors (TKI) are currently approved for patients with an activating epidermal growth factor receptor (EGFR) mutation or anaplastic ...

    journal_title：Cancer treatment reviews

    pub_type： 杂志文章,评审

    doi：10.1016/j.ctrv.2015.05.005

    authors： Hendriks LE,Schoenmaekers J,Zindler JD,Eekers DB,Hoeben A,De Ruysscher DK,Dingemans AM

    更新日期：2015-07-01 00:00:00

  • Risk of morbidity and mortality from cardiovascular disease following radiotherapy for childhood cancer: a systematic review.

    abstract：PURPOSE:To evaluate the existing evidence regarding the long-term risk of cardiovascular disease (CVD) after radiotherapy for childhood cancer. PATIENTS AND METHODS:MEDLINE and EMBASE were searched for articles reporting on radiation-induced CVD after childhood cancer published between 1966 and October 2002. Informati...

    journal_title：Cancer treatment reviews

    pub_type： 杂志文章,评审

    doi：10.1016/j.ctrv.2005.03.008

    authors： van der Pal HJ,van Dalen EC,Kremer LC,Bakker PJ,van Leeuwen FE

    更新日期：2005-05-01 00:00:00

  • Low dose cyclophosphamide: Mechanisms of T cell modulation.

    abstract：:Cyclophosphamide is considered one of the most successful chemotherapy drugs and is listed on the World Health Organisations List of Essential Medicines. Since its initial synthesis in 1958, it has been widely used to treat a range of cancers but its use has been declining due to the advent of platinum based and other...

    journal_title：Cancer treatment reviews

    pub_type： 杂志文章,评审

    doi：10.1016/j.ctrv.2015.11.005

    authors： Madondo MT,Quinn M,Plebanski M

    更新日期：2016-01-01 00:00:00

  • A systematic review and meta-analysis of randomised trials of neo-adjuvant hormone therapy for localised and locally advanced prostate carcinoma.

    abstract：BACKGROUND:We performed a systematic review and meta-analysis of randomised trials of neo-adjuvant hormone therapy (NHT) in localised and locally advanced prostate cancer to assess the effectiveness of this therapy. METHODS:We searched MEDLINE, The Cochrane Library, Science Citation Index, LILACS and SIGLE for randomi...

    journal_title：Cancer treatment reviews

    pub_type： 杂志文章,meta分析,评审

    doi：10.1016/j.ctrv.2008.08.002

    authors： Shelley MD,Kumar S,Wilt T,Staffurth J,Coles B,Mason MD

    更新日期：2009-02-01 00:00:00

  • Management of brain metastasized non-small cell lung cancer (NSCLC) - From local treatment to new systemic therapies.

    abstract：:Lung cancer has the highest frequency of brain dissemination compared to all other solid tumours. Classical treatment options such as brain irradiation have started to be questioned due to lack of survival benefit and risk for severe side effects. Oncogenic driven tumours have the highest frequency of brain disseminat...

    journal_title：Cancer treatment reviews

    pub_type： 杂志文章,评审

    doi：10.1016/j.ctrv.2017.02.004

    authors： Tsakonas G,De Petris L,Ekman S

    更新日期：2017-03-01 00:00:00

  • Evolving concepts in the management of drug resistant ovarian cancer: dose dense chemotherapy and the reversal of clinical platinum resistance.

    abstract：:Despite the initially high response rate to standard front-line debulking surgery followed by platinum-based chemotherapy, the relapse rate in ovarian cancer is high and many patients will recur within 6 months of completing platinum based treatment. These patients may still require further chemotherapy despite being ...

    journal_title：Cancer treatment reviews

    pub_type： 杂志文章,评审

    doi：10.1016/j.ctrv.2012.04.004

    authors： Pinato DJ,Graham J,Gabra H,Sharma R

    更新日期：2013-04-01 00:00:00

  • To what extent is alcohol consumption associated with breast cancer recurrence and second primary breast cancer?: A systematic review.

    abstract：BACKGROUND:The association between alcohol intake and breast cancer recurrence or development of second primary breast cancer in the survivor population is unclear. The aim of this systematic review was to evaluate the existing evidence to assess the extent to which alcohol consumption is associated with breast cancer ...

    journal_title：Cancer treatment reviews

    pub_type： 杂志文章,评审

    doi：10.1016/j.ctrv.2016.09.010

    authors： Simapivapan P,Boltong A,Hodge A

    更新日期：2016-11-01 00:00:00

  • Review of conditioning regimens for haplo-identical donor transplants using post-transplant cyclophosphamide in recipients of G-CSF mobilised peripheral stem cell.

    abstract：:Haplo-identical transplant is being increasingly used in patients who do not have a readily available matched related or unrelated donor. Post-transplant cyclophosphamide's use due to its simplicity and documented efficacy has made this approach readily employable across diverse transplant centres across the globe. Th...

    journal_title：Cancer treatment reviews

    pub_type： 杂志文章,评审

    doi：10.1016/j.ctrv.2020.102071

    authors： Patil S,Potter V,Mohty M

    更新日期：2020-09-01 00:00:00

  • Targeting fibroblast growth factor receptors and immune checkpoint inhibitors for the treatment of advanced bladder cancer: New direction and New Hope.

    abstract：:Bladder cancer is one of the leading causes of death in Europe and the United States. About 25% of patients with bladder cancer have advanced disease (muscle-invasive or metastatic disease) at presentation and are candidates for systemic chemotherapy. In the setting of metastatic disease, use of cisplatin-based regime...

    journal_title：Cancer treatment reviews

    pub_type： 杂志文章,评审

    doi：10.1016/j.ctrv.2016.09.018

    authors： Morales-Barrera R,Suárez C,de Castro AM,Racca F,Valverde C,Maldonado X,Bastaros JM,Morote J,Carles J

    更新日期：2016-11-01 00:00:00

  • Primary and acquired resistance mechanisms to immune checkpoint inhibition in Hodgkin lymphoma.

    abstract：:Hodgkin lymphoma is a B cell derived malignancy characterized by a low number of tumor cells within an environment consisting of inflammatory cells. Recently, immune checkpoint blockade targeting the PD-1-PD-L1 axis has shown to be a great success in relapsed and refractory Hodgkin lymphoma patients. However, complete...

    journal_title：Cancer treatment reviews

    pub_type： 杂志文章,评审

    doi：10.1016/j.ctrv.2019.101931

    authors： Veldman J,Visser L,Berg AVD,Diepstra A

    更新日期：2020-01-01 00:00:00

  • Fertility preservation in women with borderline ovarian tumours.

    abstract：:Borderline ovarian tumours (BOT) may occur in young women and have an excellent survival rate. Therefore, there is the obligation to put emphasis on fertility preservation in affected women. On the other hand, it has also been underlined that the disease should be managed with caution because these tumours can relapse...

    journal_title：Cancer treatment reviews

    pub_type： 杂志文章,评审

    doi：10.1016/j.ctrv.2016.06.010

    authors： Mangili G,Somigliana E,Giorgione V,Martinelli F,Filippi F,Petrella MC,Candiani M,Peccatori F

    更新日期：2016-09-01 00:00:00

  • Practical management of tyrosine kinase inhibitor-associated side effects in GIST.

    abstract：:Patients diagnosed with advanced gastrointestinal stromal tumor (GIST) are currently treated with oral tyrosine kinase inhibitors (TKIs). Imatinib mesylate is the standard first-line treatment, and sunitinib malate is administered second-line for patients who are intolerant or progress on imatinib. Imatinib has recent...

    journal_title：Cancer treatment reviews

    pub_type： 杂志文章,评审

    doi：10.1016/j.ctrv.2010.04.008

    authors： Joensuu H,Trent JC,Reichardt P

    更新日期：2011-02-01 00:00:00

  • The role of tumour budding in predicting survival in patients with primary operable colorectal cancer: a systematic review.

    abstract：:Tumour budding reflects a detachment of tumour cells at the invasive front of carcinomas and is presumed to be an early step in the metastatic process. Tumour budding has received some attention in colorectal cancer as it has been proposed as an additional prognostic factor in colorectal cancer that may stratify patie...

    journal_title：Cancer treatment reviews

    pub_type： 杂志文章,评审

    doi：10.1016/j.ctrv.2014.12.007

    authors： van Wyk HC,Park J,Roxburgh C,Horgan P,Foulis A,McMillan DC

    更新日期：2015-02-01 00:00:00

  • Current status and future perspectives in gastric cancer management.

    abstract：:Gastric cancer is still a major health problem and a leading cause of cancer mortality despite a worldwide decline in incidence. Environmental and Helicobacter pylori (Hp) acting early in life in a multistep and multifactorial process may cause intestinal type carcinomas, whereas genetic abnormalities are related more...

    journal_title：Cancer treatment reviews

    pub_type： 杂志文章,评审

    doi：10.1053/ctrv.2000.0164

    authors： Roukos DH

    更新日期：2000-08-01 00:00:00

  • Early diagnosis and surgical management of prostate cancer.

    abstract：:Prostate cancer is a significant cause of morbidity and mortality in the United States and Europe. The natural ageing of the population as well as the continued and widespread use of diagnostic tests such as prostate specific antigen (PSA), has led to an increase in the numbers of men diagnosed with localised prostate...

    journal_title：Cancer treatment reviews

    pub_type： 杂志文章,评审

    doi：10.1016/s0305-7372(03)00096-3

    authors： Linton KD,Hamdy FC

    更新日期：2003-06-01 00:00:00